Shield Therapeutics upbeat as Accrufer trial initiated in Japan
(Alliance News) - Shield Therapeutics PLC on Friday reported the commencement of a phase two Accrufer trial in Japan for the treatment of pulmonary arterial hypertension. Read More
| Price | 11.25p on 19-12-2025 at 19:25:08 |
|---|---|
| Change | -0.50p -4.26% |
| Buy | 11.50p |
| Sell | 11.00p |
| Last Trade: | Buy 8.00 at 11.50p |
| Day's Volume: | 1,215,868 |
| Last Close: | 11.25p |
| Open: | 11.75p |
| ISIN: | GB00BYV81293 |
| Day's Range | 11.25p - 11.75p |
| 52wk Range: | 2.20p - 12.35p |
| Market Capitalisation: | £119.45m |
| VWAP: | 11.54937p |
| Shares in Issue: | 1.06b |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Shield Thera (STX) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 8 | 11.50p | SI Trade |
16:29:35 - 19-Dec-25 |
| Sell* | 14 | 11.00p | SI Trade |
16:29:35 - 19-Dec-25 |
| Buy* | 82 | 11.50p | SI Trade |
16:29:35 - 19-Dec-25 |
| Sell* | 9,045 | 11.10p | Ordinary |
16:29:26 - 19-Dec-25 |
| Buy* | 100 | 11.50p | SI Trade |
16:22:58 - 19-Dec-25 |
| Buy* | 2,500 | 11.50p | SI Trade |
16:22:58 - 19-Dec-25 |
| Buy* | 100 | 11.50p | SI Trade |
16:22:58 - 19-Dec-25 |
| Buy* | 86 | 11.50p | SI Trade |
16:22:58 - 19-Dec-25 |
| Buy* | 22 | 11.50p | SI Trade |
16:22:58 - 19-Dec-25 |
| Buy* | 2,550 | 11.50p | SI Trade |
16:22:58 - 19-Dec-25 |
Shield Thera (STX) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 18th Dec 2025 7:13 am | RNS | Block Listing Application |
| 11th Dec 2025 7:00 am | RNS-R | Shield Wins Gold at Titan Branding Awards |
| 3rd Dec 2025 7:04 am | RNS | Amends Senior Secured Debt Financing |
| 14th Nov 2025 7:03 am | RNS | Initiation of a Phase II Clinical Trial in Japan |
| 11th Nov 2025 7:00 am | RNS | ACCRUFeR Pediatric PK Results to be Presented |
| 7th Nov 2025 7:03 am | RNS | ACCRUFeR receives Authorisation by Korean Ministry |
| 23rd Oct 2025 7:00 am | RNS | Q3 2025 Trading Update |
| 14th Oct 2025 3:01 pm | RNS | Grant of Share Options to Chief Executive Officer |
| 1st Oct 2025 8:00 am | RNS | Total Voting Rights |
| 1st Oct 2025 7:02 am | RNS | Positive efficacy and tolerance in pediatric trial |